The stock of Immune Design Corp (NASDAQ:IMDZ) is a huge mover today! About 85,128 shares traded hands. Immune Design Corp (NASDAQ:IMDZ) has declined 64.16% since April 5, 2016 and is downtrending. It has underperformed by 66.12% the S&P500.
The move comes after 9 months positive chart setup for the $130.52 million company. It was reported on Nov, 7 by Barchart.com. We have $12.77 PT which if reached, will make NASDAQ:IMDZ worth $164.46 million more.
Analysts await Immune Design Corp (NASDAQ:IMDZ) to report earnings on November, 10. They expect $-0.68 EPS, down 83.78% or $0.31 from last year’s $-0.37 per share. After $-0.71 actual EPS reported by Immune Design Corp for the previous quarter, Wall Street now forecasts -4.23% EPS growth.
Immune Design Corp (NASDAQ:IMDZ) Ratings Coverage
Out of 2 analysts covering Immune Design (NASDAQ:IMDZ), 2 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Immune Design has been the topic of 4 analyst reports since August 18, 2015 according to StockzIntelligence Inc. The rating was initiated by Leerink Swann on Tuesday, August 18 with “Outperform”. The stock has “Buy” rating given by Jefferies on Wednesday, September 9. As per Wednesday, August 10, the company rating was maintained by Jefferies.
According to Zacks Investment Research, “Immune Design Corp. is a clinical-stage immunotherapy company. The Company is focused on the development of immune-based therapies based on its DCVex (TM) and GLAAS (TM) discovery platforms for cancer and other chronic conditions. Its product candidates in Phase I clinical trials comprise LV305, CMB305, and G305 for the treatment of solid tumor types, such as breast cancer, melanoma, non-small cell lung cancer, ovarian cancer, or sarcoma; and G100 for the treatment of patients with merkel cell carcinoma. Immune Design Corp. is headquartered in Seattle, Washington.”
Insitutional Activity: The institutional sentiment increased to 1.25 in Q2 2016. Its up 0.21, from 1.04 in 2016Q1. The ratio is positive, as 8 funds sold all Immune Design Corp shares owned while 16 reduced positions. 8 funds bought stakes while 22 increased positions. They now own 9.57 million shares or 12.34% less from 10.92 million shares in 2016Q1.
Springbok Cap Limited Liability Co holds 800 shares or 0% of its portfolio. State Street Corp owns 207,670 shares or 0% of their US portfolio. Pnc Finance Services last reported 76 shares in the company. Credit Suisse Ag accumulated 13,524 shares or 0% of the stock. Wells Fargo And Mn holds 0% or 4,208 shares in its portfolio. Highbridge Cap holds 0% of its portfolio in Immune Design Corp (NASDAQ:IMDZ) for 26,452 shares. Spark Inv Mngmt Lc has 77,500 shares for 0.06% of their US portfolio. Blackrock Limited accumulated 0% or 2,713 shares. Teacher Retirement Systems Of Texas, a Texas-based fund reported 1,129 shares. Proquest Assocs Iv Limited holds 1.96M shares or 6.51% of its portfolio. Rs Inv Mngmt Com Ltd Llc holds 0.1% of its portfolio in Immune Design Corp (NASDAQ:IMDZ) for 1.23M shares. Tfs Capital Limited Liability Company holds 102,685 shares or 0.15% of its portfolio. National Bank & Trust Of America De holds 1,422 shares or 0% of its portfolio. Vanguard Gp holds 0% or 334,933 shares in its portfolio. Walleye Trading Ltd Liability Company owns 200 shares or 0% of their US portfolio.
Insider Transactions: Since July 15, 2016, the stock had 4 buys, and 0 selling transactions for $10.26 million net activity. Shares for $5.00 million were bought by Svennilson Peter. $250,000 worth of shares were bought by COLEMAN LEWIS W on Tuesday, September 20. 800,000 shares were bought by COLUMN GROUP L P, worth $5.00M. Another trade for 1,500 shares valued at $10,255 was made by Brady Stephen R on Friday, July 15.
More news for Immune Design Corp (NASDAQ:IMDZ) were recently published by: Quotes.Wsj.com, which released: “News Immune Design Corp.IMDZ” on July 23, 2014. Globenewswire.com‘s article titled: “Immune Design and Gritstone Oncology Announce Clinical Collaboration for …” and published on May 09, 2016 is yet another important article.
IMDZ Company Profile
Immune Design Corp., incorporated on February 20, 2008, is a clinical-stage immunotherapy company. The Firm focuses on cancer with in vivo approaches designed to enable the body’s immune system to fight disease. The Firm is developing multiple product candidates from its discovery platforms, including ZVex and GLAAS. ZVex is a discovery platform that uses a vector to generate product candidates designed to create cytotoxic T cells (CTLs) in vivo. The ZVex vector is a delivery system based on a hybrid, re-engineered virus designed to carry the genetic information of selected tumor antigen in whole or selected epitopes selectively to dendritic cells (DCs) in the skin. When injected into a cancer patient, a ZVex product candidate is designed to interact only with these DCs, delivering the tumor antigen in the form of ribonucleic acid (RNA).
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.